Identification of a novel metabolic and lipidomic signature for 90-day functional outcome after ischemic stroke: an exploratory proof-of-concept study.
Wang T, Ji J, et al. • Frontiers in neurology • 2026
Integrated serum metabolomics and lipidomics identified a metabolic signature reflecting lipotoxicity, mitochondrial dysfunction, and oxidative stress that showed promising discriminatory potential (AUC = 0.950) for 90-day functional outcome after ischemic stroke.
Key Findings
Results
Patients with unfavorable 90-day outcomes after ischemic stroke exhibited global metabolic reprogramming characterized by structural lipid disassembly, mitochondrial energy failure, and antioxidant depletion.
Study enrolled 44 patients with acute ischemic stroke stratified by favorable (n=23) or unfavorable (n=21) 90-day functional outcomes
Structural lipid disassembly was characterized by widespread reductions in membrane phospholipids, including phosphatidylcholines and ether phospholipids
Mitochondrial energy failure was evidenced by acylcarnitine abnormalities consistent with impaired β-oxidation
Antioxidant depletion was marked by decreased cis-caffeic acid in the unfavorable outcome group
Results
An exploratory three-marker panel demonstrated promising discriminatory potential for unfavorable 90-day functional outcome after ischemic stroke.
The three-marker panel consisted of the C8:2-OH(3)/C18:2-OH(3) ratio, the free DHA/PC(44:12) ratio, and cis-caffeic acid
The panel achieved an AUC of 0.950 in the derivation cohort
This panel was identified through integrated serum metabolomic and lipidomic profiling
Authors note these results are from a derivation cohort only and should be viewed as hypothesis-generating without external validation
Results
Adding the three-marker metabolic panel to the initial NIHSS score improved discriminatory performance for unfavorable functional outcome beyond clinical assessment alone.
NIHSS score alone had a lower AUC than the combined model
Adding the metabolic panel to the initial NIHSS score improved the AUC to 0.975
This suggests incremental value of the molecular phenotyping panel beyond conventional clinical scales
The authors caution that without external validation and multiple-testing correction, these results should be viewed as hypothesis-generating
Results
Membrane phospholipid reductions, specifically in phosphatidylcholines and ether phospholipids, were identified as a key feature of unfavorable stroke outcomes.
Widespread reductions in phosphatidylcholines were observed in patients with unfavorable outcomes
Ether phospholipids were also markedly reduced in the unfavorable outcome group
These changes were interpreted as reflecting structural lipid disassembly
The free DHA/PC(44:12) ratio was one of the three candidate markers selected for the panel, reflecting altered phospholipid metabolism
Results
Acylcarnitine abnormalities consistent with impaired β-oxidation were observed in patients with unfavorable functional outcomes.
Acylcarnitine abnormalities were identified through serum metabolomic profiling
These abnormalities were interpreted as consistent with mitochondrial energy failure and impaired β-oxidation
The C8:2-OH(3)/C18:2-OH(3) ratio, a hydroxylated acylcarnitine ratio, was included as one of the three candidate biomarkers
This finding was characterized as part of broader systemic metabolic reprogramming in unfavorable outcome patients
Background
This was an exploratory proof-of-concept study with important methodological limitations including small sample size, lack of external validation, and absence of multiple-testing correction.
Total sample size was 44 patients (23 favorable, 21 unfavorable outcomes)
The study is described as a 'derivation cohort' without external validation
No multiple-testing correction was applied to the differential metabolite and lipid analyses
Authors explicitly state 'these results should be viewed as hypothesis-generating'
The study is described as an 'exploratory proof-of-concept study' throughout
What This Means
This research suggests that patients who recover poorly after an ischemic stroke show distinct patterns in the molecules circulating in their blood compared to those who recover well. By analyzing blood samples from 44 stroke patients and measuring hundreds of metabolites and lipids, researchers found that those with poor recovery showed signs of three major problems: breakdown of cell membrane fats (particularly phospholipids), disrupted energy production in the cellular powerhouses (mitochondria), and reduced levels of antioxidants. These differences were detectable in the blood shortly after the stroke occurred.
The researchers used these findings to develop a three-marker blood test panel that combined measurements of certain fat-related molecules and an antioxidant compound called cis-caffeic acid. In this initial group of patients, the panel was very good at predicting who would have poor recovery at 90 days, achieving an AUC (a measure of accuracy) of 0.950, where 1.0 would be perfect. When this panel was added to the standard clinical stroke severity score (NIHSS), the combined approach performed even better, with an AUC of 0.975, suggesting the blood markers add useful information beyond what doctors can assess clinically.
This research matters because better prediction of stroke recovery could help doctors identify high-risk patients earlier and potentially guide more aggressive treatment or rehabilitation efforts. However, it is critical to note that this was a small exploratory study of only 44 patients without an independent validation group, and the statistical analyses were not corrected for the large number of comparisons made. The authors themselves emphasize these findings are hypothesis-generating only and must be confirmed in larger, independent studies before any clinical application could be considered.
Wang T, Ji J, Wang M, Fan R, Ye Y, Zhang S, et al.. (2026). Identification of a novel metabolic and lipidomic signature for 90-day functional outcome after ischemic stroke: an exploratory proof-of-concept study.. Frontiers in neurology. https://doi.org/10.3389/fneur.2026.1931495